Behavioral dysfunctions (BPSD) represent the most important problem in Alzheimer’s dementia (AD) management. We assessed the serum levels of two myokines in AD patients, preliminary investigating, as secondary aim, their role as potential biomarkers for agitation/aggression (AA) and aberrant motor behavior (AMB): irisin, since it is able to modify the motor pattern, and BDNF, since it was transcribed following irisin stimulation. Forty AD patients were recruited and characterized according to the expressed neuropsychiatric syndrome. Myokines were measured by ELISA. Irisin serum levels were slightly elevated in AA+ patients (+ 10.0%; p < 0.05) and correlated with the duration of AA (r = 0.74, p < 0.03). BDNF failed to show such differences. We propose that these selected myokines are not useful as surrogate markers for agitation in AD, but might represent interesting secondary outcomes when testing drugs for those BPSD implying elevated motor activity.

Irisin and BDNF serum levels and behavioral disturbances in Alzheimer’s disease / E. Conti, D. Grana, G. Stefanoni, A. Corsini, M. Botta, P. Magni, A. Aliprandi, C. Lunetta, I. Appollonio, C. Ferrarese, L. Tremolizzo. - In: NEUROLOGICAL SCIENCES. - ISSN 1590-1874. - 40:6(2019), pp. 1145-1150. [10.1007/s10072-019-03781-y]

Irisin and BDNF serum levels and behavioral disturbances in Alzheimer’s disease

A. Corsini;P. Magni;
2019

Abstract

Behavioral dysfunctions (BPSD) represent the most important problem in Alzheimer’s dementia (AD) management. We assessed the serum levels of two myokines in AD patients, preliminary investigating, as secondary aim, their role as potential biomarkers for agitation/aggression (AA) and aberrant motor behavior (AMB): irisin, since it is able to modify the motor pattern, and BDNF, since it was transcribed following irisin stimulation. Forty AD patients were recruited and characterized according to the expressed neuropsychiatric syndrome. Myokines were measured by ELISA. Irisin serum levels were slightly elevated in AA+ patients (+ 10.0%; p < 0.05) and correlated with the duration of AA (r = 0.74, p < 0.03). BDNF failed to show such differences. We propose that these selected myokines are not useful as surrogate markers for agitation in AD, but might represent interesting secondary outcomes when testing drugs for those BPSD implying elevated motor activity.
Alzheimer’s disease; BDNF; BPSD; Irisin; Myokines; Aged; Aged, 80 and over; Aggression; Alzheimer Disease; Biomarkers; Brain-Derived Neurotrophic Factor; Female; Fibronectins; Humans; Male; Psychomotor Agitation
Settore MED/04 - Patologia Generale
Settore MED/05 - Patologia Clinica
Settore MED/13 - Endocrinologia
2019
Article (author)
File in questo prodotto:
File Dimensione Formato  
Conti2019_Article_IrisinAndBDNFSerumLevelsAndBeh.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 412.94 kB
Formato Adobe PDF
412.94 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/698806
Citazioni
  • ???jsp.display-item.citation.pmc??? 6
  • Scopus 13
  • ???jsp.display-item.citation.isi??? 13
social impact